Compare KPTI & TGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KPTI | TGE |
|---|---|---|
| Founded | 2008 | 2023 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Newspapers/Magazines |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.6M | 85.8M |
| IPO Year | 2013 | N/A |
| Metric | KPTI | TGE |
|---|---|---|
| Price | $6.53 | $1.18 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $22.17 | N/A |
| AVG Volume (30 Days) | 131.2K | ★ 275.7K |
| Earning Date | 11-03-2025 | 10-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.48 |
| Revenue | ★ $142,530,000.00 | $130,212,000.00 |
| Revenue This Year | $3.82 | N/A |
| Revenue Next Year | $3.18 | N/A |
| P/E Ratio | ★ N/A | $2.28 |
| Revenue Growth | N/A | ★ 316.50 |
| 52 Week Low | $3.51 | $0.78 |
| 52 Week High | $12.45 | $37.02 |
| Indicator | KPTI | TGE |
|---|---|---|
| Relative Strength Index (RSI) | 61.76 | N/A |
| Support Level | $5.70 | N/A |
| Resistance Level | $6.05 | N/A |
| Average True Range (ATR) | 0.41 | 0.00 |
| MACD | 0.10 | 0.00 |
| Stochastic Oscillator | 84.89 | 0.00 |
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
The Generation Essentials Group is a media and entertainment company. Its publications L'Officiel and The Art Newspaper publish print editions in a total of nearly 28 countries and territories and digital contents. It operate in the movie production sector having produced various Asia-focused movies. It operate in three operating segments: media and entertainment segment, hotel operations, hospitality and VIP services segment and strategic investment segment. Key revenue is generated from strategic investment segment that is engage in proprietary investments and management of portfolio, including listed and unlisted equity shares investments and movie income right investments.